WellSpring Pharma Services, a contract development and manufacturing organization for solid, semi-solid and non-sterile liquid products, has announced a $3 million capital investment in new equipment as well as a new strategic partnership with IDT Australia Ltd. to manufacture drugs targeting the US market.

The capital investment enables new, directly scalable capabilities in smaller development-scale equipment; expanded manufacturing for specialized dosage forms such as bilayer tablets; and improved support for high-potency compound manufacturing.

Among the equipment added during the capitalization were an Alexanderwerk Roller Compactor; an IMA Precisa capsule weight checker; a 400 kg O'Hara Tray Drying oven; a Korsch XL 400 Tablet Press with bilayer module; a Glatt GPCG 2/5 Fluid Bed Processor; an O'Hara Aqueous Film Coater with 18″ and 30″ interchangeable pans; and a 5L Becomix Counter sweep vessel.

IDT Australia concluded a manufacturing and supply agreement with WellSpring for WellSpring to produce several products at the WellSpring facility near Toronto, including Pindolol, a cardiac drug with an estimated US market value of $10 million.

Source: WellSpring Pharma Services